Abbott Laboratories intends to sell fixed-rate notes in six tranches

By Devika Patel

Knoxville, Tenn., Nov. 17 – Abbott Laboratories plans to offer fixed-rate notes in six parts, according to a 424B5 filing with the Securities and Exchange Commission.

The notes will be due in 2019, 2021, 2023, 2026, 2036 and 2046. They have make-whole calls and par calls.

BofA Merrill Lynch, Barclays and Morgan Stanley & Co. LLC are the bookrunners.

Proceeds will be used to fund the cash portion of the Abbott Park, Ill., pharmaceutical health care products company’s planned $25 billion acquisition of St. Jude Medical, Inc. and for general corporate purposes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.